Zobrazeno 1 - 10
of 177
pro vyhledávání: '"Nozomu, Machida"'
Autor:
Tadayoshi Hashimoto, Yoshiaki Nakamura, Yoshito Komatsu, Satoshi Yuki, Naoki Takahashi, Naohiro Okano, Hidekazu Hirano, Koushiro Ohtsubo, Takashi Ohta, Eiji Oki, Tomohiro Nishina, Hisateru Yasui, Hisato Kawakami, Taito Esaki, Nozomu Machida, Ayako Doi, Shogen Boku, Toshihiro Kudo, Yoshiyuki Yamamoto, Akiyoshi Kanazawa, Tadamichi Denda, Masahiro Goto, Naoko Iida, Hiroshi Ozaki, Taro Shibuki, Mitsuho Imai, Takao Fujisawa, Hideaki Bando, Yoichi Naito, Takayuki Yoshino
Publikováno v:
BJC Reports, Vol 2, Iss 1, Pp 1-10 (2024)
Abstract Background While advanced gastrointestinal stromal tumors (GISTs) are primarily treated with tyrosine kinase inhibitors (TKIs), acquired resistance from specific mutations in KIT or PDGFRA frequently occurs. We aimed to assess the utility of
Externí odkaz:
https://doaj.org/article/8d89e02235024fa88d2552871e8438cb
Autor:
Ajay Goel, Yuya Yoshimoto, Yate-Ching Yuan, Takashi Ogata, Hiroyuki Katoh, Yoshiyuki Suzuki, Fumiaki Takahashi, Takashi Oshima, Daisaku Yoshida, Alessandra Nardin, Michael Fehlings, Kosaku Mimura, Phuong H D Nguyen, Souvick Roy, Hassen Kared, Shotaro Nakajima, Hisashi Sato, Nozomu Machida, Takanobu Yamada, Yohei Watanabe, Tomoaki Tamaki, Hirohito Fujikawa, Yasuhiro Inokuchi, Suguru Hayase, Hiroyuki Hanayama, Zenichiro Saze, Koji Kono
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 1 (2024)
Background Tumor-associated antigen (TAA)-specific CD8(+) T cells are essential for nivolumab therapy, and irradiation has been reported to have the potential to generate and activate TAA-specific CD8(+) T cells. However, mechanistic insights of T-ce
Externí odkaz:
https://doaj.org/article/4ebaa04ef7ec4c62ba91fa761c93160d
Autor:
Kosaku Mimura, Takashi Ogata, Yuya Yoshimoto, Daisaku Yoshida, Shotaro Nakajima, Hisashi Sato, Nozomu Machida, Takanobu Yamada, Yohei Watanabe, Tomoaki Tamaki, Hirohito Fujikawa, Yasuhiro Inokuchi, Suguru Hayase, Hiroyuki Hanayama, Zenichiro Saze, Hiroyuki Katoh, Fumiaki Takahashi, Takashi Oshima, Yoshiyuki Suzuki, Koji Kono
Publikováno v:
Communications Medicine, Vol 3, Iss 1, Pp 1-7 (2023)
Abstract Background Although immune checkpoint inhibitors (ICI) targeting for PD-1 axis is a promising approach for advanced gastric cancer (GC) patients, the response rate is still limited. Induction of synergistic effect of irradiation with ICI tar
Externí odkaz:
https://doaj.org/article/34bfc099e4d543cbbe2a9cdc0e794b94
Autor:
Hayato Watanabe, Hirohito Fujikawa, Keisuke Komori, Kazuki Kano, Kosuke Takahashi, Takanobu Yamada, Yasuhiro Inokuchi, Nozomu Machida, Tomoyuki Yokose, Yasushi Rino, Munetaka Masuda, Takashi Ogata, Takashi Oshima
Publikováno v:
Case Reports in Gastroenterology, Vol 15, Iss 2, Pp 562-567 (2021)
There are few reports of conversion surgery (CS) after nivolumab monotherapy because it is considered as a third-line standard chemotherapy for unresectable or recurrent gastric cancer. Here, we report a rare case of stage IV gastric cancer effective
Externí odkaz:
https://doaj.org/article/1b157b8caeaf4295bf221a016dcc80d3
Autor:
Yasuhiro Inokuchi, Kota Washimi, Mamoru Watanabe, Kei Hayashi, Yoshihiro Kaneta, Mitsuhiro Furuta, Nozomu Machida, Shin Maeda
Publikováno v:
Clinical Case Reports, Vol 10, Iss 6, Pp n/a-n/a (2022)
Abstract Heterotopic gastric gland (HGG)‐originating early gastric cancer was endoscopically resected. We resected the HGG, widely marked the perimeter outside the submucosal tumor‐like area, injected from outside the markings into the submucosa,
Externí odkaz:
https://doaj.org/article/1ab9830aef804b4ab5acce63f471a019
Autor:
Yasuhiro Inokuchi, Kei Hayashi, Yoshihiro Kaneta, Yoichiro Okubo, Mamoru Watanabe, Mitsuhiro Furuta, Nozomu Machida, Shin Maeda
Publikováno v:
Therapeutic Advances in Gastrointestinal Endoscopy, Vol 15 (2022)
Introduction: Duodenal neuroendocrine tumors (DNETs) smaller than 1 cm in diameter, without invasion to the muscularis propria, have a low risk of metastasis. Therefore, DNETs are frequently resected endoscopically. However, among the various procedu
Externí odkaz:
https://doaj.org/article/c4c4068844d84a6e8ca19503c79287d5
Autor:
Itaru Hashimoto, Kazuki Kano, Shizune Onuma, Hideaki Suematsu, Shinsuke Nagasawa, Kyohei Kanematsu, Kyoko Furusawa, Tomomi Hamaguchi, Mamoru Watanabe, Kei Hayashi, Mitsuhiro Furuta, Yasuhiro Inokuchi, Nozomu Machida, Toru Aoyama, Takanobu Yamada, Yasushi Rino, Takashi Ogata, Takashi Oshima
Publikováno v:
Journal of Personalized Medicine, Vol 13, Iss 6, p 923 (2023)
Trifluridine/tipiracil (FTD/TPI) is an oral anticancer agent used as a third- or later-line treatment for patients with metastatic gastric cancer/gastroesophageal junction cancer (mGC/GEJC). The C-reactive protein-to-serum albumin ratio (CAR) is an i
Externí odkaz:
https://doaj.org/article/832f6b9f97774c12ad5c97e5da9d4a3f
Autor:
Sadayuki Kawai, Naoki Fukuda, Shun Yamamoto, Seiichiro Mitani, Katsuhiro Omae, Takeru Wakatsuki, Ken Kato, Shigenori Kadowaki, Daisuke Takahari, Narikazu Boku, Kei Muro, Nozomu Machida
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-9 (2020)
Abstract Background Ramucirumab monotherapy as a second-line treatment for advanced gastric cancer (AGC) prolongs survival compared to the best supportive care. However, in clinical practice, ramucirumab monotherapy is sometimes used as third- or lat
Externí odkaz:
https://doaj.org/article/eb8b100e1efb473587bd1cadee493b61
Autor:
KEI HAYASHI, MITSUHIRO FURUTA, KYOKO FURUSAWA, TOMOMI HAMAGUCHI, MAMORU WATANABE, YASUHIRO INOKUCHI, SHIZUNE ONUMA, ITARU HASHIMOTO, HIDEAKI SUEMATSU, SHINSUKE NAGASAWA, KYOHEI KANEMATSU, TAKANOBU YAMADA, AKIFUMI NOTSU, TAKASHI OGATA, TAKASHI OSHIMA, NOZOMU MACHIDA, JUNJI FURUSE, SHIN MAEDA
Publikováno v:
Anticancer Research. 43:2831-2840
Autor:
ITARU HASHIMOTO, KAZUKI KANO, SHIZUNE ONUMA, HIDEAKI SUEMATSU, SHINSUKE NAGASAWA, KYOHEI KANEMATSU, KYOKO FURUSAWA, TOMOMI HAMAGUCHI, MAMORU WATANABE, KEI HAYASHI, MITSUHIRO FURUTA, YASUHIRO INOKUCHI, NOZOMU MACHIDA, TORU AOYAMA, TAKANOBU YAMADA, YASUSHI RINO, TAKASHI OGATA, TAKASHI OSHIMA
Publikováno v:
Anticancer Research. 43:1689-1697